Faculty Information - OKUYAMA Ryo

■ Education

1.	2014/04～2019/06	〔Doctorial Course〕, Tokyo Institute of Technology, Completed, Doctor of Management of Technology
2.	2010/04～2012/03	Tokyo Institute of Technology, Completed,
3.	2004/04	〔Other〕, The University of Tokyo,
4.	1991/04～1993/03	〔Master Course〕, The University of Tokyo, Completed,

■ Academic and professional experience

1.	2010/04～2015/03	Head
2.	1993/04～2010/03	Researcher

■ Current specialized field

Business administration

■ Books and theses

1.	2025/05	Article	Toward Establishing a Japanese Drug Discovery Ecosystem: The Role of Startups and a Model Tailored to Japan. (Single)
2.	2025/04	Article	National Granted Programs and Public Funds for Biopharmaceutical Startups in Japan. Pharmacology Research & Perspectives 13,pp.e70106 (Single)
3.	2025	Book	Chapter 3. Drug Repurposing for Psychiatric Diseases. In Drug Repurposing: Chemistry, Biochemistry & Red Biotechnology (Ed.M.N.Gupta) pp.44-61 (Collaboration)
4.	2024/11	Article	Leveraging Corporate Assets and Talent to Attract Investors in Japan: A Country with an Innovation System Centered on Large Companies. Journal of Risk and Financial Management 17(12),pp.539 (Single)
5.	2024/10	Article	Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines. Journal of Market Access & Health Policy 12(4),pp.317-325 (Single)
6.	2024/03	Article	Trends in COVID-19 Vaccine Development: Vaccine Platform, Developer, and Nationality. Vaccines 12(3),pp.259 (Single)
7.	2024/02	Article	Increased contribution of small companies to late-entry drugs: a changing trend in FDA-approved drugs during the 2020s. Drug Discovery Today 29(2),pp.103866 (Single)
8.	2023/12	Article	Academia’s contribution to drug discovery: current status and perspectives in Japan. Translational and Regulatory Sciences 5(3),pp.57-64 (Single)
9.	2023/11	Article	mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions. Vaccines 11(12),pp.1737 (Single)
10.	2023/07	Article	Advancements in Drug Repurposing: Examples in Psychiatric Medications. International Journal of Molecular Sciences 24(13),pp.11000 (Single)
11.	2023/06	Article	Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin. Pharmaceutics 15(7),pp.1794 (Single)
12.	2023/05	Article	Strengthening the Competitiveness of Japan’s Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan’s Highly Productive Firm. Biological and Pharmaceutical Bulletin 46(5),pp.718-724 (Single)
13.	2023/04	Article	Modality diversification and best-in-class small-molecule drugs: Recent trend of orphan drug development. Medicine in Drug Discovery 18,pp.100156 (Single)
14.	2022/12	Article	Nurturing Deep Tech to Solve Social Problems: Learning from COVID-19 mRNA Vaccine Development. Pathogens 11(12),pp.1469 (Single)
15.	2020/06	Article	Importance of drug target selection capability for new drug innovation: definition, fostering process and interaction with organizational management. Prometheus 36(2),pp.135-152 (Collaboration)
16.	2017/02	Article	Importance of tacit knowledge in incremental innovation: Implications from drug discovery cases Journal of Strategy and Management 10(1),pp.118-130 (Single)
17.	2015/12	Article	The types of scientific information and technologies acquired from university-industry relationships in the Japanese pharmaceutical industry - An empirical study from 1980 to 2012 International Journal of Technology Transfer and Commercialisation 13(3/4),pp.178-191 (Single)
18.	2014/07	Article	Acquisition of drug candidates in New Drug Development in Japan Proceedings of Portland International Center for Management of Engineering and Technology (Collaboration)
19.	2013/07	Article	University-Industry Collaboration in Drug Discovery in Japan: An Empirical Analysis over Thirty Years Proceedings of Portland International Center for Management of Engineering and Technology (Collaboration)
20.	2013/06	Article	Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes ACS Med Chem Lett. 4(8),pp.790-794 (Collaboration)
21.	2013/05	Article	Aminopyrazole–Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies ACS Med. Chem. Lett. 4(9),pp.829-834 (Collaboration)
22.	2012/10	Article	Phenylalanine Derivatives as GPR142 Agonists for the Treatment of Type II Diabetes Bioorg Med Chem Lett. 22(19),pp.6218-6223 (Collaboration)
23.	2012/07	Article	Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus Bioorg Med Chem Lett. 22(18),pp.5942-5947 (Collaboration)
24.	2011/01	Article	Pharmacology and in Vitro Profiling of a Novel Peroxisome Proliferator-Activated Receptor γ Ligand, Cerco-A. Biol Pharm Bull. 34(7),pp.1094-1104 (Collaboration)
25.	2009/10	Article	Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2- pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats. Bioorg Med Chem Lett. 20(1),pp.341-345 (Collaboration)
26.	2009/08	Article	Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol -2-yl]benzamide Bioorg Med Chem Lett. 19(15),pp.4151-4158 (Collaboration)
27.	2009/08	Article	Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl) thiazol-2-yl]benzamide and its biological evaluation Bioorg Med Chem Lett. 19(15),pp.4159-4166 (Collaboration)
28.	2007/01	Article	In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides Nucleic Acids Symp Ser (Oxf). 51,pp.111-112 (Collaboration)
29.	2006/09	Article	Direct comparison of in vivo antisense activity of ENAregistered oligonucleotides targeting PTP1B mRNA with that of 2'-MOE-modified oligonucleotides Oligonucleotides 16,pp.253-262 (Collaboration)
30.	2005/06	Article	Turnover and Characterization of UDP-N-Acetylglucosaminyl Transferase (OGT) in a Stably Transfected HeLa Cell Line Biochem. Biophys. Res. Commun. 332(1),pp.263-270 (Collaboration)
31.	2005/04	Article	Glucosamine Induces Rapid Desensitization of Glucose Transport in Isolated Adipocytes by Increasing GlcN-6-P Levels Biochem. Biophys. Res. Commun. 329(3),pp.1155-1161 (Collaboration)
32.	2005/04	Article	Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry Anal. Chem. 77(7),pp.2050-2055 (Collaboration)
33.	2004/08	Article	Potential Regulation of Nuclear UDP-N-acetylglucosaminyl Transferase (OGT) by Substrate Availability : Ability of Chromatin Protein to Bind UDP-N-acetylglucosamine and Reduce OGT-mediated O-linked Glycosylation Biol. Pham. Bull. 27(8),pp.1293-1296 (Collaboration)
34.	2004/06	Article	Differential Effects of Vanadate on UDP-N-Acetylglucosaminyl Transferase (OGT) Activity Derived from Cytosol and Nucleosol Biochem. Biophys. Res. Commun. 318(4),pp.911-915 (Collaboration)
35.	2003/09	Article	UDP-N-acetylglucosaminyl Transferase (OGT) in Brain Tissue: Temperature Sensitivity and Subcellular Distribution of Cytosolic and Nuclear Enzyme J. Neurochem. 86(5),pp.1271-1280 (Collaboration)
36.	2003/06	Article	High Glucose Potentiates Palmitate-induced NO-mediated Cytotoxicity through Generation of Superoxide in Clonal Beta-cell HIT-T15 FEBS Lett. 545(2-3),pp.219-223 (Collaboration)
37.	2003/03	Article	Measurement of UDP-N-Acetylglucosaminyl Transferase (OGT) in Brain Cytosol and Characterization of Anti-OGT Antibodies Anal. Biochem. 314(2),pp.169-179 (Collaboration)
38.	2001/09	Article	Cytosolic O-GlcNAc Accumulation is not Involved in Beta-cell Death in HIT-T15 or Min6 Biochem. Biophys. Res. Commun. 287(2),pp.366-371 (Collaboration)
39.	1994/10	Article	Differential Potentiation by Depolarization of the Effects of Calcium Antagonists on Contraction and Ca2+ Current in Guinea-pig Heart Br. J. Pharmacol. 113(2),pp.451-456 (Collaboration)
40.	1993/02	Article	Quaternary Diltiazem Can Act from Both Sides of the Membrane in Ventricular Myocytes Jpn. J. Pharmacol. 61(3),pp.263-266 (Collaboration)
Display 5 items
Display all(40)

■ Conference presentations

1.

2024/11/30

An attempt to analyze Japanese technology startups using a large-scale database (Asia Pacific Conference 2024)

■ Works

1.	2024/05/24	Innovation System for Drug Discovery in Japan: Current Status, Challenges and Solutions
2.	2017/09/11	Expectation for star scientists project from pharmaceutical company

■ Awards and honors

1.	2024/07	Ritsumeikan Asia Pacific University AY2023 Research Excellence Award
2.	2023/07	Ritsumeikan Asia Pacific University AY2022 Research Award
3.	2023/05	The Pharmaceutical Society of Japan Highlighted paper selected by Editor-in-Chief (Strengthening the Competitiveness of Japan’s Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan’s Highly Productive Firm)

■ E-Mail address

■ External Researcher ID

orcID

0000-0002-9820-7741